Cart
sales@molnova.com
TAK-041
CAS No. 1929519-13-0
TAK-041( NBI-1065846 )
Catalog No. M28601 CAS No. 1929519-13-0
TAK-041 is a potent and selective GPR139 agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 260 | In Stock |
|
| 10MG | 430 | In Stock |
|
| 25MG | 710 | In Stock |
|
| 50MG | 972 | In Stock |
|
| 100MG | 1341 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-041
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-041 is a potent and selective GPR139 agonist.
-
DescriptionTAK-041 is a potent and selective GPR139 agonist.
-
In Vitro——
-
In VivoAnimal Model:BALB/c mice Dosage:0.03, 0.3, and 3 mg/kg Administration:P.o.Result:Dose-dependently improved the social behavior of BALB/c mice.
-
SynonymsNBI-1065846
-
PathwayCell Cycle/DNA Damage
-
TargetGPR
-
RecptorPDE5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1929519-13-0
-
Formula Weight392.33
-
Molecular FormulaC18H15F3N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (254.89 mM)
-
SMILESC[C@@H](c(cc1)ccc1OC(F)(F)F)NC(CN1N=Nc(cccc2)c2C1=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wolf-Georg Forssmann, et al. Use of phosphodiesterase inhibitors in the treatment of prostatic diseases. US 8106061 B2
molnova catalog
related products
-
SB271046
SB271046 is a potent, selective and orally active 5-HT6 receptor antagonist with pKi of 8.9, exhibits 200-fold greater selectivity over other 5-HT receptor subtypes.
-
P2Y2R/GPR17 antagoni...
P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual antagonist with an IC50 of 3.17 μM for P2Y2R and 1.67 μM for GPR17.
-
WAY-298630
(2-{[2-(2-fluorophenoxy)ethyl]sulfanyl}-1H-benzimidazol-1-yl)acetic acid is a prostaglandin-like CRTH2 antagonist with an IC50 < 10 μM, which can be used in studies of rhinitis, COPD, rheumatoid arthritis, eczema and conjunctivitis.
